CEO Marcio Souza walks us through essential tremor and the mechanism of ulixacaltamide, and also comments on a recent seizure trial that did not succeed. Plus, preparing for potential commercial launches and how he thinks about M&A. Coverage brought to you by

Marcio Souza describes Praxis' small molecule and antisense oligonucleotide platforms, and previews key trials that will have near term data